title: CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment.
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha. yonghao.cao@yale.edu david.pitt@yale.edu.
authors.forename: Yonghao
authors.initials: Y
authors.lastname: Cao
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: Alyssa
authors.initials: A
authors.lastname: Nylander
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: Sriram
authors.initials: S
authors.lastname: Ramanan
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: Brittany A
authors.initials: BA
authors.lastname: Goods
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: Gerald
authors.initials: G
authors.lastname: Ponath
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: Rana
authors.initials: R
authors.lastname: Zabad
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: Veronica L S
authors.initials: VL
authors.lastname: Chiang
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: Alexander O
authors.initials: AO
authors.lastname: Vortmeyer
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha.
authors.forename: David A
authors.initials: DA
authors.lastname: Hafler
authors.affiliation: From the Yale School of Medicine (Y.C., A.N., S.R., G.P., V.L.S.C., A.O.V., D.A.H., D.P.), New Haven, CT; Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (B.A.G.), Cambridge; and University of Nebraska Medical Center (R.Z.), Omaha. yonghao.cao@yale.edu david.pitt@yale.edu.
authors.forename: David
authors.initials: D
authors.lastname: Pitt
mesh_terms: D000368:Aged; D018791:CD4 Lymphocyte Count; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000276:immunology*; D005260:Female; D006801:Humans; D000074324:Ipilimumab / Q000009:adverse effects*
chemical_list: D000074324:Ipilimumab